这篇综述总结了接受全身治疗的晚期黑色素瘤患者生存护理的最新进展，并强调了需要更多研究的领域。在过去的十年中，晚期和转移性黑色素瘤的治疗取得了显着的进展。由于这些新的治疗方法，包括几种免疫检查点抑制剂和酪氨酸激酶抑制剂，已经并将继续增加接受全身治疗的黑色素瘤长期幸存者的数量。这些患者将面临新的挑战，因为他们基本上是这些新疗法之后的第一批长期幸存者。幸存者护理的重点是改善患者与健康相关的生活质量，包括从诊断开始一直持续到生命终结的癌症对身体、情感、社会和功能的影响。生存还包括筛查癌症复发和第二癌症。随着接受全身治疗的黑色素瘤幸存者数量持续增长，即使在癌症治疗后，幸存者护理计划对于患者的最佳护理也将变得越来越重要。了解这组患者生存护理的多个领域对于他们现在的护理和确定未来研究中未满足的需求至关重要。© 2024。作者获得 Springer Science Business Media, LLC（Springer 旗下公司）的独家许可自然。

This review summarizes the latest advancements in survivorship care for patients with advanced melanoma who received systemic therapy and emphasizes the areas where more research is needed.Over the last decade there have been remarkable advances in the treatment of advanced and metastatic melanoma. Due to these novel treatments, including several immune checkpoint inhibitors and tyrosine kinase inhibitors, there are and will continue to be increasing numbers of long-term melanoma survivors who have been treated with systemic therapy. These patients will navigate new challenges are they are essentially among the first long term survivors after these novel therapies. Survivorship care focuses on improving the health-related quality of life of patients including the physical, emotional, social and functional effects of cancer that begin at diagnosis and continue through the end of life. Survivorship also includes screening for cancer recurrence and second cancers. As the number of melanoma survivors who received systemic therapy continues to grow, the survivorship care plan will become increasingly important for optimal care of patients even after their cancer treatments. Understanding the many domains of survivorship care for this group of patients is imperative for their care now and to identify unmet needs for future research.© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.